Bristol-Myers Squibb has agreed to pay $1.1 million as part of settlement charges in the Plavix case, which was being investigated by the New York State Attorney General's Office, reported Reuters.
Subscribe to our email newsletter
As part of the settlement, Bristol-Myers also owned up its role in depriving consumers of cheaper generic versions of its drugs Buspar and Taxol, the news source reported.
In 2007, Bristol-Myers faced allegations that it illegally concealed a side deal with the generic drugmaker Apotex to block the release of a generic form of Bristol’s blood-thinning drug Plavix. However, Bristol-Myers pleaded guilty to the charges and paid around $150 million to the states. The company also agreed to notify the states of patent litigation settlements with generic drug competitors.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.